Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPRO

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRO
DateTimeSourceHeadlineSymbolCompany
07/03/202400:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
29/02/202400:05GlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
27/02/202400:05GlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
10/02/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
06/02/202412:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202412:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202412:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202412:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202412:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
06/02/202408:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
01/02/202408:05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
08/01/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
06/01/202400:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
06/01/202400:05GlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
05/01/202408:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
03/01/202400:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
03/01/202400:05GlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
16/11/202308:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
16/11/202308:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
14/11/202308:50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
14/11/202308:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
14/11/202308:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
14/11/202308:05GlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
14/11/202308:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
13/11/202322:45IH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
07/11/202300:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:SPROSpero Therapeutics Inc
02/11/202307:05GlobeNewswire Inc.Spero Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SPROSpero Therapeutics Inc
01/11/202323:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
01/11/202323:05GlobeNewswire Inc.Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerNASDAQ:SPROSpero Therapeutics Inc
01/11/202307:05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SPRO